Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis

Jill S. Fischer*, Roger L. Priore, Lawrence D. Jacobs, Diane L. Cookfair, Richard A. Rudick, Robert M. Herndon, John R. Richert, Andres M. Salazar, Donald E. Goodkin, Carl V. Granger, Jack H. Simon, Jordan H. Grafman, Muriel D. Lezak, Kathleen M. O'Reilly Hovey, Katherine Kawczak Perkins, Danielle Barilla-Clark, Mark Schacter, David W. Shucard, Anna L. Davidson, Karl E. WendeDennis N. Bourdette, Mariska F. Kooijmans-Coutinho

*Corresponding author for this work

Research output: Contribution to journalArticle

281 Citations (Scopus)

Abstract

Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined effects of treatment on neuropsychological (NP) performance. To evaluate the effects of interferon β-1a (IFNβ-1a, 30 μg administered intramuscularly once weekly [Avonex]) on cognitive function, a Comprehensive NP Battery was administered at baseline and week 104 to relapsing MS patients in the phase III study, 166 of whom completed both assessments. A Brief NP Battery was also administered at 6-month intervals. The primary NP outcome measure was 2-year change on the Comprehensive NP Battery, grouped into domains of information processing and learning/memory (set A), visuospatial abilities and problem solving (set B), and verbal abilities and attention span (set C). NP effects were most pronounced in cognitive domains vulnerable to MS: IFNβ-1a had a significant beneficial effect on the set A composite, with a favorable trend evident on set B. Secondary outcome analyses revealed significant between-group differences in slopes for Brief NP Battery performance and time to sustained deterioration in a Paced Auditory Serial Addition Test processing rate, favoring the IFNβ-1a group. These results support and extend previous observations of significant beneficial effects of IFNβ-1a for relapsing MS.

Original languageEnglish (US)
Pages (from-to)885-892
Number of pages8
JournalAnnals of neurology
Volume48
Issue number6
DOIs
StatePublished - Dec 19 2000

Fingerprint

Interferons
Multiple Sclerosis
Aptitude
Automatic Data Processing
Cognition
Outcome Assessment (Health Care)
Learning
Therapeutics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Fischer, J. S., Priore, R. L., Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., ... Kooijmans-Coutinho, M. F. (2000). Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. Annals of neurology, 48(6), 885-892. https://doi.org/10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1
Fischer, Jill S. ; Priore, Roger L. ; Jacobs, Lawrence D. ; Cookfair, Diane L. ; Rudick, Richard A. ; Herndon, Robert M. ; Richert, John R. ; Salazar, Andres M. ; Goodkin, Donald E. ; Granger, Carl V. ; Simon, Jack H. ; Grafman, Jordan H. ; Lezak, Muriel D. ; O'Reilly Hovey, Kathleen M. ; Perkins, Katherine Kawczak ; Barilla-Clark, Danielle ; Schacter, Mark ; Shucard, David W. ; Davidson, Anna L. ; Wende, Karl E. ; Bourdette, Dennis N. ; Kooijmans-Coutinho, Mariska F. / Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. In: Annals of neurology. 2000 ; Vol. 48, No. 6. pp. 885-892.
@article{da696edfff3c447a9988114a828af2d6,
title = "Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis",
abstract = "Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined effects of treatment on neuropsychological (NP) performance. To evaluate the effects of interferon β-1a (IFNβ-1a, 30 μg administered intramuscularly once weekly [Avonex]) on cognitive function, a Comprehensive NP Battery was administered at baseline and week 104 to relapsing MS patients in the phase III study, 166 of whom completed both assessments. A Brief NP Battery was also administered at 6-month intervals. The primary NP outcome measure was 2-year change on the Comprehensive NP Battery, grouped into domains of information processing and learning/memory (set A), visuospatial abilities and problem solving (set B), and verbal abilities and attention span (set C). NP effects were most pronounced in cognitive domains vulnerable to MS: IFNβ-1a had a significant beneficial effect on the set A composite, with a favorable trend evident on set B. Secondary outcome analyses revealed significant between-group differences in slopes for Brief NP Battery performance and time to sustained deterioration in a Paced Auditory Serial Addition Test processing rate, favoring the IFNβ-1a group. These results support and extend previous observations of significant beneficial effects of IFNβ-1a for relapsing MS.",
author = "Fischer, {Jill S.} and Priore, {Roger L.} and Jacobs, {Lawrence D.} and Cookfair, {Diane L.} and Rudick, {Richard A.} and Herndon, {Robert M.} and Richert, {John R.} and Salazar, {Andres M.} and Goodkin, {Donald E.} and Granger, {Carl V.} and Simon, {Jack H.} and Grafman, {Jordan H.} and Lezak, {Muriel D.} and {O'Reilly Hovey}, {Kathleen M.} and Perkins, {Katherine Kawczak} and Danielle Barilla-Clark and Mark Schacter and Shucard, {David W.} and Davidson, {Anna L.} and Wende, {Karl E.} and Bourdette, {Dennis N.} and Kooijmans-Coutinho, {Mariska F.}",
year = "2000",
month = "12",
day = "19",
doi = "10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1",
language = "English (US)",
volume = "48",
pages = "885--892",
journal = "Annals of Neurology",
issn = "0364-5134",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

Fischer, JS, Priore, RL, Jacobs, LD, Cookfair, DL, Rudick, RA, Herndon, RM, Richert, JR, Salazar, AM, Goodkin, DE, Granger, CV, Simon, JH, Grafman, JH, Lezak, MD, O'Reilly Hovey, KM, Perkins, KK, Barilla-Clark, D, Schacter, M, Shucard, DW, Davidson, AL, Wende, KE, Bourdette, DN & Kooijmans-Coutinho, MF 2000, 'Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis', Annals of neurology, vol. 48, no. 6, pp. 885-892. https://doi.org/10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1

Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. / Fischer, Jill S.; Priore, Roger L.; Jacobs, Lawrence D.; Cookfair, Diane L.; Rudick, Richard A.; Herndon, Robert M.; Richert, John R.; Salazar, Andres M.; Goodkin, Donald E.; Granger, Carl V.; Simon, Jack H.; Grafman, Jordan H.; Lezak, Muriel D.; O'Reilly Hovey, Kathleen M.; Perkins, Katherine Kawczak; Barilla-Clark, Danielle; Schacter, Mark; Shucard, David W.; Davidson, Anna L.; Wende, Karl E.; Bourdette, Dennis N.; Kooijmans-Coutinho, Mariska F.

In: Annals of neurology, Vol. 48, No. 6, 19.12.2000, p. 885-892.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis

AU - Fischer, Jill S.

AU - Priore, Roger L.

AU - Jacobs, Lawrence D.

AU - Cookfair, Diane L.

AU - Rudick, Richard A.

AU - Herndon, Robert M.

AU - Richert, John R.

AU - Salazar, Andres M.

AU - Goodkin, Donald E.

AU - Granger, Carl V.

AU - Simon, Jack H.

AU - Grafman, Jordan H.

AU - Lezak, Muriel D.

AU - O'Reilly Hovey, Kathleen M.

AU - Perkins, Katherine Kawczak

AU - Barilla-Clark, Danielle

AU - Schacter, Mark

AU - Shucard, David W.

AU - Davidson, Anna L.

AU - Wende, Karl E.

AU - Bourdette, Dennis N.

AU - Kooijmans-Coutinho, Mariska F.

PY - 2000/12/19

Y1 - 2000/12/19

N2 - Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined effects of treatment on neuropsychological (NP) performance. To evaluate the effects of interferon β-1a (IFNβ-1a, 30 μg administered intramuscularly once weekly [Avonex]) on cognitive function, a Comprehensive NP Battery was administered at baseline and week 104 to relapsing MS patients in the phase III study, 166 of whom completed both assessments. A Brief NP Battery was also administered at 6-month intervals. The primary NP outcome measure was 2-year change on the Comprehensive NP Battery, grouped into domains of information processing and learning/memory (set A), visuospatial abilities and problem solving (set B), and verbal abilities and attention span (set C). NP effects were most pronounced in cognitive domains vulnerable to MS: IFNβ-1a had a significant beneficial effect on the set A composite, with a favorable trend evident on set B. Secondary outcome analyses revealed significant between-group differences in slopes for Brief NP Battery performance and time to sustained deterioration in a Paced Auditory Serial Addition Test processing rate, favoring the IFNβ-1a group. These results support and extend previous observations of significant beneficial effects of IFNβ-1a for relapsing MS.

AB - Cognitive dysfunction is common in multiple sclerosis (MS), yet few studies have examined effects of treatment on neuropsychological (NP) performance. To evaluate the effects of interferon β-1a (IFNβ-1a, 30 μg administered intramuscularly once weekly [Avonex]) on cognitive function, a Comprehensive NP Battery was administered at baseline and week 104 to relapsing MS patients in the phase III study, 166 of whom completed both assessments. A Brief NP Battery was also administered at 6-month intervals. The primary NP outcome measure was 2-year change on the Comprehensive NP Battery, grouped into domains of information processing and learning/memory (set A), visuospatial abilities and problem solving (set B), and verbal abilities and attention span (set C). NP effects were most pronounced in cognitive domains vulnerable to MS: IFNβ-1a had a significant beneficial effect on the set A composite, with a favorable trend evident on set B. Secondary outcome analyses revealed significant between-group differences in slopes for Brief NP Battery performance and time to sustained deterioration in a Paced Auditory Serial Addition Test processing rate, favoring the IFNβ-1a group. These results support and extend previous observations of significant beneficial effects of IFNβ-1a for relapsing MS.

UR - http://www.scopus.com/inward/record.url?scp=0033663893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033663893&partnerID=8YFLogxK

U2 - 10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1

DO - 10.1002/1531-8249(200012)48:6<885::AID-ANA9>3.0.CO;2-1

M3 - Article

C2 - 11117545

AN - SCOPUS:0033663893

VL - 48

SP - 885

EP - 892

JO - Annals of Neurology

JF - Annals of Neurology

SN - 0364-5134

IS - 6

ER -